ArticleScientific reports2026
Irisin modulates the transcriptomic profile of porcine anterior pituitary cells isolated from gilts on days 15-16 of pregnancy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Irisin, an adipomyokine primarily known for its role in metabolic regulation, has recently emerged as a potential regulator of reproductive function. While its ovarian actions have been partially characterised, its influence on the anterior pituitary remains largely unexplored. This study aimed to investigate the in vitro effects of irisin on the transcriptome of porcine anterior pituitary cells (APc) isolated from gilts on days 15-16 of pregnancy. Primary APc were isolated from pigs on days 15-16 of pregnancy and treated with 300 ng/mL of irisin. RNA sequencing (NovaSeq 6000, Illumina) was performed to identify differentially expressed genes (DEGs), long non-coding RNAs (lncRNAs), and alternative splicing (AS) events. Functional annotation was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Selected transcripts were validated by polymerase chain reaction (PCR) and quantitative PCR (qPCR). Irisin treatment altered the expression of 500 genes, 747 lncRNAs, and 245 transcripts undergoing AS events. Differentially expressed genes were enriched in pathways related to hormonal signalling, angiogenesis, calcium signalling, and cell remodelling. Notably, genes encoding key regulators of these processes, such as growth hormone 1, insulin-like growth factor type 1, somatostatin, prolactin receptor, and progesterone receptor, were modulated. Pathway enrichment analysis indicated enrichment of genes assigned to Janus kinase/signal transducer and activator of transcription, phosphoinositide 3-kinase/protein kinase B, and mitogen-activated protein kinase signalling cascades. This study provides the first comprehensive transcriptomic profiles of irisin action on porcine APc during early pregnancy. Irisin can modulate endocrine, structural, and molecular functions through both transcriptional and post-transcriptional mechanisms, positioning it as a novel modulator of pituitary adaptation in early gestation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.